Replies to post #370510 on Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

"Leo is in the driver's seat and he knows it. I believe Leo has been engaged in talks with various BP for quite some time because part of the EUA process is to show how you plan to manufacture and distribute the authorized drug and the U.S. Gov't has a lot say in these areas.

"When a company has an asset that others in the industry can easily value in the billion$...funding is not a problem."

If the asset (B) is so "easily valued", for so many indications over numerous years, why haven't the big boys' ponied up?

We all believe what we want.

Hopefully the B for C results are good and do not become a footnote in the Septembers 10K (or later 10 q's).

GLTU

[Justfactsmam]

Truer words haven't been spoken...

When a company has an asset that others in the industry can easily value in the billion$...funding is not a problem.

If BP is any example, Gilead did a P-2, then obtained EUAs from around the world and did a P-3 LAST. They made nearly $5B before they completed a P-3 and gained FDA approval. (Business 101)

Having or applying for the EUA is what puts Leo in the driver's seat. Potential partners are attracted to the EUA quick-cash and Leo is probably negotiating with several BP entities.

Prediction: By the time Brilacidin's Clinical Trial Results are reported...Biden Admin will be desperate for some good news to combat the Delta Variant...Brilacidin will receive EUA...AFTER P2...and NOT have to complete P3 first. Then after EUA, P3 conducted with funding/grants from BP (partner?, licensee? acquirer?) or Gov.

Also, IMO... the commencement of development of delivery alternatives (spray/inhaler, and "one-shot injection") will be funded and investigated.